Bimal Shah
Director/Board Member bei ANEBULO PHARMACEUTICALS, INC.
Profil
Bimal R.
Shah currently works at Anebulo Pharmaceuticals, Inc., as Independent Director from 2023 and Allos Therapeutics, Inc., as Chief Financial Officer & Treasurer from 2012.
Mr. Shah also formerly worked at Spectrum Pharmaceuticals, Inc., as Vice President-Corporate & Business Development from 2013 to 2021.
Mr. Shah received his undergraduate degree, graduate degree, and Masters Business Admin degree from Stanford University.
Aktive Positionen von Bimal Shah
Unternehmen | Position | Beginn |
---|---|---|
ANEBULO PHARMACEUTICALS, INC. | Director/Board Member | 05.10.2023 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Director of Finance/CFO | 05.09.2012 |
Ehemalige bekannte Positionen von Bimal Shah
Unternehmen | Position | Ende |
---|---|---|
SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2021 |
Ausbildung von Bimal Shah
Stanford University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
ANEBULO PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |